Western Michigan University

ScholarWorks at WMU
Honors Theses

Lee Honors College

4-22-2022

The Effect of Estrogen on GDNF Production of Skeletal Muscle In
Vitro
Hope Welter
Western Michigan University, hopewelter3@gmail.com

Follow this and additional works at: https://scholarworks.wmich.edu/honors_theses
Part of the Biology Commons, and the Medicine and Health Sciences Commons

Recommended Citation
Welter, Hope, "The Effect of Estrogen on GDNF Production of Skeletal Muscle In Vitro" (2022). Honors
Theses. 3575.
https://scholarworks.wmich.edu/honors_theses/3575

This Honors Thesis-Open Access is brought to you for
free and open access by the Lee Honors College at
ScholarWorks at WMU. It has been accepted for inclusion
in Honors Theses by an authorized administrator of
ScholarWorks at WMU. For more information, please
contact wmu-scholarworks@wmich.edu.

1
The Effect of Estrogen on GDNF Production by Skeletal Muscle In Vitro

Hope Welter
April 22nd, 2022

A Thesis Submitted to the Lee Honors College in Fulfillment
of the Requirement for the Bachelor’s Degree of Bachelor of Science
and for the Degree of Bachelor of Arts at Western Michigan University

Thesis Chair:
Dr. John Spitsbergen, Chair of the Dept. of Biological Sciences

Thesis Committee:
Dr. John Spitsbergen, Chair of the Dept. of Biological Sciences
Juliana VanGyseghem, PhD Candidate
Samantha Hack, PhD Candidate

2
Abstract
As life expectancy continues to rise, the number of people over age 65 in the U.S. is increasing.
An aging population brings with it impacts on the national health system and associated
economic expenditures. As individuals age, the skeletomuscular system suffers reduced function
due to disease or conditions such as sarcopenia. Sarcopenia is characterized by muscular atrophy
resulting from reduced muscle innervation. Exercise has been linked to prevention of sarcopenia,
a suspected result of increased production of glial cell line-derived neurotrophic factor (GDNF).
GDNF promotes neuronal survival, regeneration, and the formation of neuromuscular junctions.
Therefore, treatments like exercise that increase GDNF expression by skeletal muscle cells could
be used as possible preventative measures for sarcopenia. It is well known that skeletal muscle
structure differs between the sexes, and prior studies have shown that males have a higher
incidence of sarcopenia compared to females. This raises the possibility that differences in sex
hormones could be responsible for reduced muscular atrophy observed in females. Estrogen is
one such hormone that is important for sexual development in females (although it is produced in
low levels by male gonads). It is currently unclear if estrogen is responsible for neuroprotection
in female skeletal muscle. The aim of this study was to observe the effects of E2 (estradiol)
estrogen treatments on levels of GDNF production in C C skeletal muscle cells. To test this, we
treated murine myotubes with estradiol in vitro and quantified GDNF protein levels using an
enzyme-linked immunosorbent assay (ELISA). The results of this study suggest that estradiol
treatments of 5 nM and 100 nM lead to decreased GDNF production 4 hours after treatment.
When compared to the control, the 5 nM estradiol treated cells produced an increase in GDNF at
48 hours. Our data indicate that chronic estradiol exposure could increase GDNF production in
skeletal muscle in vitro, highlighting a potential mechanism by which estrogen could lead to the
reduced incidence of sarcopenia in females.
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Introduction
Significance: It is evident that with an
advancing life expectancy, the elderly
population is continuously growing in
developed countries. By the year 2050, it
is expected that 25% of the population will
be 65 years of age or older (Chen et al.,
2009). With aging, the musculoskeletal
system undergoes detrimental changes,
including decreased muscle and bone
strength (Boros & Fremont, 2017). As a
result, the elderly are more prone to
fractures and skeletal disease such as
Figure 1. Graph displaying the loss of muscle
arthritis. Not only are the elderly
mass with age (Batsis & Buscemi, 2011).
experiencing a lower quality of life, but
these effects also lead to economic expenses. In 1992, the elderly incurred the largest share of
medical costs due to musculoskeletal conditions of all age groups at about 34% of the total cost.
Along with this, fractures accounted for 36.9% of health care expenditures nationally
(Hamerman, 1997). Namely, a change in the musculoskeletal system with aging that accounts for
loss of muscle mass, or muscular atrophy, is sarcopenia. This condition results from a loss of
contact between motor neurons and skeletal muscle at the neuromuscular junction (Larsson et al.,
2019). The nervous system serves an important role in muscle maintenance, however, the
nervous system can also change over time with aging and experience, which is known as
neuroplasticity. Recent studies have made efforts to try to understand factors that regulate
neuroplasticity, although mechanisms vary across individuals and throughout life. Factors
including age and sex contribute to this variability (Voss et al., 2017).
The motor-nervous system: Also known as the peripheral nervous system, the motor-nervous
system is composed of motor neurons and the skeletal muscles they innervate. These specialized
types of neuronal cells integrate signals from the brain and sensory systems to control muscular
movement (Swetenburg et al., 2017). The motor neuron fibers have an origin in the ventral horn
of the spinal cord, and end at the neuromuscular junctions (NMJ) of skeletal muscles (Patel,
2015). The NMJ consists of a nerve terminal and a postsynaptic muscle cell, with the small space
between them known as a synapse. Ions, neurotransmitters, peptides and other signal molecules
are exocytosed from the nerve terminal, and act upon cell receptors on the postsynaptic cell. The
postsynaptic muscle fiber can then respond to the signals provided by the nerve cell (Engel,
2008). Our study focuses on effects in non-innervated skeletal muscle cells, as opposed to effects
in presynaptic motor neurons.
Glial cell line-derived neurotrophic factor (GDNF): GDNF is a neurotrophic factor for somatic
motor neurons, and is a candidate for nervous system regeneration (Storer et al., 2003). GDNF
promotes motor neuron survival (Lin et al., 1993), and has been found to be produced in skeletal
muscle with colocalization at the NMJ (Suzuki et al., 1998). Previous studies from our lab have
shown that GDNF content is affected by involuntary exercise in vivo (McCullough et al., 2011),
where higher levels were associated with a 2-week running regimen in soleus muscle.
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Alternatively, low levels of GDNF were associated with compromised structure and function at
the NMJ (Lie & Weis, 1998). In a study published in 2014, it was found that GDNF content from
C C myotubes could be affected by electrical stimulation. In a study done with electrical
stimulation of C C cells in cell culture, it was found that GDNF expression can be changed with
treatment (Vianney et al., 2014).
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Sex comparison of skeletal muscle:
Several studies have analyzed the
differences between skeletal muscle
depending on sex, drawing clear sexdependent distinctions between
fatigability (Semmler et al., 1999) and
fiber-type (Haizlip et al., 2015).
Furthermore, additional studies indicate
that the incidence of sarcopenia may be
dependent on sex, where men have a
higher prevalence of sarcopenia than
women (with adjustments for a number
of factors, including weight) (Figure 2)
(Mata Diz et al., 2015). An additional
Figure 2. The male population faces a higher prevalence
study by Khongsri et al. found similar
of sarcopenia in comparison to their female counterparts
results displaying the male population
(Mata Diz et al., 2015).
with a higher prevalence of sarcopenia in
comparison to the female population when looking at those of 60-69 and 80+ years of age
(2016). Along with this, muscle degeneration and loss of muscle strength has been found to
occur faster in males than in females, specifically those of 75 years or older (Du et al., 2019).
Estrogen: Estrogen is a hormone that interacts with the female body to regulate a woman's
menstrual cycle and reproductive development. This hormone is secreted by the ovaries,
placenta, and in the peripheral conversion tissues in women. Estrogen levels within the human
bloodstream cycle throughout the menstrual cycle and decline with age (Reed & Carr, 2018).
Estrogen interacts with estrogen receptors found on organs of the female reproductive system
and skeletal muscle, amongst others. Throughout menopause, women lose most of their estrogen,
with continued loss at each year of the process. On another note, it is present at low levels within
the male body as a vital player in male fertility and reproductive organ development. Estrogen in
males is found at low levels within the bloodstream, and higher levels in male reproductive
serums. Thus, sex is in part determined by quantitative comparisons of estrogen and the primary
male sex hormone, testosterone (Hess et al., 1997).
Estrogen is found in three major forms: estrone (E1), estradiol (E2), and estriol (E3). In this
study, estradiol was used. This form of estrogen was chosen due to its potency, and its relevance
to menopause. During menopause, the primary estrogen changes to E1 from E2. Due to our focus
on sarcopenia, which occurs during or after menopause, E2 was selected as the experimental
estrogen (Cleveland Clinic). Several studies have investigated the role of ovarian hormones on
skeletal muscle contractility, including that from Moran et al. which found that estradiol
replacement restored the decline in muscle contractility and myosin function in vivo in post-
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ovariectomy rats (2007). In a study from 2006, the authors found estrogen to be a regulator of
skeletal muscle fiber growth during recovery from disuse in female rats. In addition, estrogen
treatments were found to have direct effects on myofiber size post-injury of skeletal muscle
(McClung et al.).
Rationale: Previous work in Dr. Spitsbergen’s laboratory has shown that exercise increased
GDNF protein content and end plate area in skeletal muscle (Gyrokos et al., 2014). Along with
this, GDNF has been found to increase the number of motor neurons innervating neuromuscular
junctions, meaning that the amount of GDNF in skeletal muscle can regulate the number of
neuromuscular junctions formed (Nyugen et al., 1998). Therefore, an increase in levels of GDNF
expression in skeletal muscle due to exercise provides a possible explanation as to why exercise
has been seen to reverse and prevent sarcopenia in aging adults. Alternatives to exercise that
increase the amount of GDNF produced by skeletal muscle could provide further options of
sarcopenia prevention and treatment. The studies presented displayed clear distinctions between
skeletal muscle found in males and females, which could be due to the female sex hormone,
estrogen. Along with this, the loss of estrogen is related to the decline in muscle strength and
mass (Horstman et al., 2012). Supplemental studies presented here suggest estrogen interacts
with skeletal muscle within the female body, leading to speculation of its role in muscular
degeneration and possible regeneration. Due to the correlations between estrogen, muscle mass
preservation, and GDNF expression, I hypothesized that altering levels of estrogen in skeletal
muscle cultures would alter levels of GDNF expression. To assess whether estrogen could have
an effect on GDNF expression, I treated C C murine skeletal muscle cells with various estradiol
concentrations. Enzyme-linked immunosorbent assay (ELISA) was then used to quantify levels
of GDNF expression. The results of this study support the hypothesis that chronic estradiol
treatments could increase GDNF production by skeletal muscle cells in vitro. If the estradiol
treatments lead to changes in GDNF production in the skeletal muscle cells, these results could
provide a possible explanation as to why females experience sarcopenia at lower rates in the
human population.
2
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Materials and methods
Cell Culture: C C mouse myoblasts of an adult C3H mouse were obtained from the American
Type Culture Collection (ATCC). Handling procedures from the ATCC were adhered to. Cells
were maintained in growth medium that contained Dulbecco’s Modified Eagle Medium
(DMEM), 10% fetal bovine serum and 1% antibiotic antimycotic solution. Routine culture was
performed in 100 mm CytoOne plates. Experimental cultures were performed in 6-well plates to
confluence and allowed to differentiate. The cells were maintained so that experiments were
performed during passages 7 and 8. Plated cells were stored in a 37-degree Celsius incubator
with 5% CO .
2
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Estrogen treatment: For this experiment, estradiol concentrations of 0 nM, 1 nM, 5 nM, 10 nM
and 100 nM were added to different samples of C C skeletal muscle cells in vitro. The 0 nM
treatment acted as the control. The concentrations were varied within a relevant range to
physiological estrogen concentration. The vehicle for estradiol was ethanol, which was present at
such low concentrations that no vehicle control was necessary.
2
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To add the estradiol, 2 microliters of the estrogen solution were pipetted into each well with 2
mL of growth media. Each 6-well plate was designated to a concentration of 0 nM, 1 nM, 5 nM,
10 nM and 100 nM of estradiol. Each column in the plate was designated to a time interval of 4
hours, 24 hours, or 48 hours.
Samples of the media (1 mL) and the cells were taken separately after 4 hours of adding the
estradiol, 24 hours after, and 48 hours after. The scraped cells were stored in 1 mL sample buffer
solution. To scrape cells, a standard cell scraper was used. The 4-hour time was used to study
short-term effects, whereas the 24- and 48-hour samples were utilized to evaluate long-term
effects.
GDNF ELISA (Enzyme-linked immunosorbent assay): The standard ELISA protocol was
performed following R&D Systems MAB212 manufacturer specifications.
Statistical analysis: Differences between means were examined using Student’s t-test assuming
equal standard deviations.
Results
Previous studies have displayed a correlation between a decline in estrogen and loss of muscle
mass (Horstman et al., 2012). Here, we sought to determine if GDNF expression by skeletal
muscle could be affected by estrogen treatments. First, routine cell culture was performed with
C C murine skeletal muscle cells. Estradiol treatments of varying concentrations were
performed, and samples of both the cells and the media in which they were incubating were
obtained in intervals. ELISA was utilized to quantify the GDNF content present in samples.
Statistical analysis was performed with ELISA results to analyze GDNF content in the cells and
the media with varying estradiol treatments. The experiment had a sample size of n=4. Results
displayed significant changes in GDNF production of skeletal muscle cells treated with 5 nM and
100 nM estradiol solutions.
2
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Figure 3 displays data from a representative concentration showing a comparison of GDNF
content between the cell and media samples. The cells were collected 4 hours after a 1nM
estradiol treatment. The results show that the majority of GDNF produced is retained within cells
and not found in incubating media. Due to undetectable GDNF levels in the media samples by
the ELISA, the cells alone were further analyzed.
Figure 3. Changes in cellular GDNF content
(pg/mL) following estradiol treatment. C C
skeletal muscle cells were grown in cell
culture and treated with 1 nM estradiol
solutions. Cell and media samples were
collected 4 hours after treatment. ELISA was
used to quantify GDNF concentration in the
samples. Cells collected 4 hours after 1 nM
treatment retained GDNF produced. 3 out of 4
experiments show 0 pg/mL GDNF
concentration in media.
2

12

7
Figure 4 displays the average GDNF concentration (pg/mL) found in the cell samples collected 4
hours after treatment. These results show that the cells treated with concentrations of 5 nM and
100 nM of estradiol produced a statistically significant decreased amount of GDNF in
comparison to the control at this time interval.
Figure 4. GDNF content (pg/mL) found in cell
samples collected 4 hours after treatment.
Myotubes in cell culture were treated with varying
estradiol doses and samples were collected 4 hours
later. GDNF production was quantified using
ELISA. T-test analysis was performed following
mean calculations of GDNF content for n=4.
Significant results are represented with an asterisk
(*), indicating a p-value < 0.05. Data shown
represent mean +/- standard error of the mean.
Results show a significant decrease in GDNF
concentration in cells treated with 5 nM and 100
nM estradiol solutions in comparison to the
control.

Figure 5 displays the results of average GDNF content measured in the cell samples collected 24
hours after the various estradiol treatments. Statistical analysis produced no significant data.
Figure 5. GDNF concentration (pg/mL)
in cell samples collected 24 hours after
treatment. Murine skeletal muscle cells in
culture were treated with varying estradiol
concentrations and samples were
collected 24 hours after. ELISA was used
to quantify GDNF in samples. T-test
analysis was performed following mean
calculations of GDNF content for n=4.
Significant results are represented with an
asterisk (*), indicating a p-value < 0.05.
Data shown represent mean +/- standard
error of the mean. Results showed no
significance.
Figure 6 shows the results of average GDNF content found in the cell samples collected 48 hours
after estradiol treatment. The results display a significant increase in GDNF concentration found
in cells treated with 5 nM estradiol in comparison to the control.
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Figure 6. GDNF concentration (pg/mL) found
in cell samples collected 48 hours after
estradiol treatments. C C skeletal myotubes
were treated with varying estradiol concentrated
solutions and cellular samples were collected 48
hours later. GDNF concentration was quantified
with ELISA. T-test analysis was performed
following mean calculations of GDNF content
for n=4. Significant results are represented with
an asterisk (*), indicating a p-value < 0.05. Data
shown represent mean +/- standard error of the
mean. Results show a significant increase in
GDNF concentration in cells treated with 5 nM
in comparison to the control.
2
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Figure 7 represents a comparison between the cells treated with 5nM and the control using
average GDNF concentration in the samples at each time interval. The results show a significant
difference in GDNF production between the treated and untreated cells at 4 hours and 48 hours
after treatment. At 4 hours, the treated cells appeared to produce a decrease in GDNF production,
whereas at 48 hours there was an apparent increase.

Figure 7. GDNF concentration (pg/mL) for cells treated with 5
nM estradiol compared to the control.
Skeletal muscle cells were treated with 5 nM estradiol in vitro,
and samples were collected at various time intervals after
treatment. Control cells were not treated with estradiol.
Statistical analysis was done using a t-test to compare 5nM
treated cells with the control. Asterisks (*) indicate significance,
or a p-value < 0.05. Data shown represent mean +/- standard
error of the mean. The results show significant differences in
GDNF produced between treated and untreated cells at 4 hours
and 48 hours after treatment. No significance was found at 24
hours.
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Figure 8 represents a comparison between the cells treated with 100nM and the control using
average GDNF concentration in the samples at each time interval. The results suggest a
significant decrease in GDNF production between the treated and untreated cells at 4 hours.
Although there is no significant difference in the GDNF produced at 48 hours, preliminary data
suggests a trend towards increased GDNF production by treated cells at this concentration.

Figure 8. GDNF concentration (pg/mL) for cells treated
with 100 nM estradiol compared to the control. Skeletal
muscle cells were treated with 100 nM estradiol in vitro, and
samples were collected at various time intervals after
treatment. Control cells were not treated with estradiol.
Statistical analysis was done using a t-test to compare
100nM treated cells with the control. Asterisks (*) indicate
significance, or a p-value < 0.05. Data shown represent mean
+/- standard error of the mean. The results show significant
differences in GDNF produced between treated and
untreated cells at 4 hours after treatment. No significance
was found at 24 and 48 hours.

Discussion
The primary goal of the present study was to determine the effects of treatment with estradiol on
GDNF expression in C C skeletal muscle myotubes in cell culture. To do this, C C cells were
treated with estradiol at various concentrations and samples were taken at specific time
intervals. ELISA assays were used to quantify GDNF protein concentration in the cells and in the
media samples after treatment. The results of this study suggest that: 1.) the majority of GDNF
produced is found within cells with little being released in medium, 2.) estradiol treatment with
5nM and 100nM appeared to cause a decrease in GDNF production and 3.) cells collected 4
hours after a 5 nM estradiol treatment produced an increased amount of GDNF in comparison to
the control.
2
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The results from this present study are consistent with those produced in a study investigating the
effects of electrical stimulation on GDNF production (Vianney et al., 2014). First, both studies
found that treated myotubes retained the GDNF they produced. Here, this was found specifically
in cells sampled 4 hours after treatment, independent of the estradiol concentration added. These
results suggest stored GDNF could be secreted based upon a system of demand. In an in vivo
model, this could be due to a need for GDNF by spinal motor neurons. The in vitro model used
here may not have allowed for this demand to be met, therefore no GDNF secretion was
detected. Second, both studies showed differences in GDNF production with acute and chronic
treatments. Acute treatments displayed inhibitory effects on GDNF production, whereas chronic
treatments suggested stimulation of GDNF production in cell samples. Specifically in this study,
these differences were seen in 5 nM and 100 nM estradiol treatments acutely, and 5 nM estradiol
treatments alone chronically. These results suggest that estradiol exposure may cause changes in
skeletal muscle cells that alters GDNF production, which changes from inhibition to stimulation
over time.
Naturally, estradiol is found in human blood at concentrations of 0.11 nM - 1.47 nM in
premenopausal women, and 0 nM - 0.11 nM in postmenopausal women (University of Rochester
Medical Center). Therefore, the 5nM estradiol treatment used in this study is in the range of
physiologically relevant and could represent the concentration found at estradiol receptors in
skeletal tissue.
In summary, the results of this study showed that GDNF produced by myotubes was not secreted
into the media, and that chronic exposure to 5 nM estradiol treatments lead to increased GDNF
production by these cells. Acute exposure of 5 nM and 100 nM estradiol treatments appeared to
have decreased GDNF production by the cells. The results support the hypothesis that chronic
estradiol treatments could increase GDNF production by skeletal muscle cells in vitro. If
estradiol treatments increased GDNF production, this may provide an explanation as to why
females experience sarcopenia resistance in comparison to their male counterparts. Additionally,
these results may suggest that an estradiol therapy could help relieve sarcopenia symptoms.
Based upon observations of cell differentiation during estrogen treatments, future studies of
importance would be those that investigate the role of estrogen in development of skeletal
muscle cells. Additionally, if time permitted, a real-time polymerase chain reaction (PCR) for
mRNA quantitation would allow for information to be given about the presence and type of
estrogen receptors in the skeletal muscle cells tested. Along with this, a replication of this study
with progesterone would provide a better understanding of what hormones impact GDNF in
skeletal muscle cells. Lastly, an experimental design that would allow for longer-term studies of
the effects of the 100 nM estradiol treatment would allow for a better understanding of the
effects of estradiol on skeletal muscle with time.
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